Phenotypic profiles and functional genomics in Alzheimer's disease and in dementia with a vascular component

Neurological Research

Volumn 26, Issue 5, 2004, Pages 459-480

  Cacabelos, Ramón ^a   Fernández Novoa, Lucía ^b   Corzo, Lola ^b   Amado, Luís ^b   Pichel, Victor ^b   Lombardi, Valter ^b   Kubota, Yasuhiko ^b  

^a Centro de Investigacion Biomedica EuroEspes   (Spain)

^b NONE

Author keywords

Alzheimer disease; APOE; Brain atrophy; Brain hemodynamics; Brain perfusion; Functional genomics; Structural genomics; Vascular dementia

Indexed keywords

ALKALINE PHOSPHATASE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LACTATE DEHYDROGENASE; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD FLOW VELOCITY; BRAIN ATROPHY; BRAIN BLOOD FLOW; BRAIN PERFUSION; CALCIUM HOMEOSTASIS; CARDIOVASCULAR FUNCTION; CLUSTER ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; ENVIRONMENTAL FACTOR; FEMALE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOMICS; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; PREVALENCE; THYROID FUNCTION;

ALZHEIMER DISEASE; ANTHROPOMETRY; APOLIPOPROTEINS E; CARDIOVASCULAR PHYSIOLOGY; DEMENTIA, VASCULAR; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; HUMANS; PHENOTYPE; VARIATION (GENETICS);

EID: 3042846712     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164104225017677     Document Type: Article

References (82)

1. Cacabelos R. Handbook of Neurogeriatrics. Alzheimer Disease and Other Dementias. Epidemiology and Genetics. Barcelona: Masson, 1999
2. Cacabelos R. Dementia. In: Jobe TH, Gaviria M, Kovilparambil A, eds. Clinical Psychiatry, Boston, MA: Blackwell Science, 1997, pp. 73-122
3. de la Torre J, Kalaria R, Nakajima K, et al., eds. Alzheimer's Disease. Vascular Etiology and Pathology. Ann NY Acad Sci, Vol. 977, 2002
4. Grant WB, Campbell A, Itzhaki RF, et al. The significance of environmental factors in the etiology of Alzheimer's disease. J Alzheimer Dis 2002; 4: 179-189
5. Selkoe DJ. Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 2001; 81: 741-766
6. Prohovnik I, Wade J, Knezevic S, et al., eds. Vascular Dementia. Current Concepts. Chichester: Wiley, 1996
7. Chiu E, Gustafson L, Ames D, et al., eds. Cerebrovascular Disease and Dementia. London: Martin Dunitz, 2000
8. Cacabelos R, Fernández-Novoa L, Lombardi V, et al. Cerebrovascular risk factors in Alzheimer's disease: Brain hemodynamics and pharmacogenomic implications. Neurol Res 2003; 25: 567-580
9. Cacabelos R. Psychogeriatric research. A conceptual introduction to geriatric neuroscience. Psychogeriatrics 2001; 1: 158-188
10. de la Torre J, Hachinski V, eds. Cerebrovascular pathology in Alzheimer's disease. Ann NY Acad Sci Vol. 826, 1997
11. Kalaria RN, Ince P, eds. Vascular Factors in Alzheimer's Disease. Ann NY Acad Sci Vol. 903, 2000
12. Aliev G, Smith MA, Obrenovich ME, et al. Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Alzheimer disease. Neurotox Res 2003; 5: 491-504
13. Eckert A, Keil U, Marques CA, et al. Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. Biochem Pharmacol 2003; 66: 1627-1634
14. Riazanskaia N, Lukiw WJ, Grigorenko A, et al. Regulatory region variability in the human presenilin-2 (PSEN2) gene: Potential contribution to the gene activity and risk for AD. Mol Psychiatry 2002; 7: 891-898
15. Shea TB, Rogers E, Ashline D, et al. Apolipoprotein E deficiency promotes increased oxidative stress and compensatory increases in antioxidants in brain tissue. Free Radical Biol Med 2002; 33: 1115-1120
16. Chan SL, Culmsee C, Haughey N, et al. Presenilin-1 mutations sensitize neurons to DNA damage-induced death by a mechanism involving perturbed calcium homeostasis and activation of calpains and caspase-12. Neurobiol Dis 2002; 11: 2-19
17. Polidori MC, Mecocci P. Plasma susceptibility to free radical-induced antioxidant consumption and lipid peroxidation is increased in very old subjects with Alzheimer disease. J Alzheimer Dis 2002; 4: 517-522
18. Marques CA, Keil U, Bonert A, et al. Neurotoxic mechanisms caused by the Alzheimer's disease-linked Swedish amyloid precursor protein mutation: Oxidative stress, caspases, and the JNK pathway. J Biol Chem 2003; 278: 28294-28302
19. Ghidoni R, Gasparini L, Alberdici A, et al. Inhibition of energy metabolism down-regulates the Alzheimer related presenilin 2 gene. J Neural Transm 2003; 110: 1029-1039
20. Bazan NG, Colangelo V, Lukiw WJ. Prostaglandins and other lipid mediators in Alzheimer's Disease. Prostaglandins Lipid Mediat 2002; 68-69: 197-210
21. Neely MD, Montine TJ. CSF lipoproteins and Alzheimer's disease. J Nutr Health Aging 2002; 6: 383-391
22. Bjorkhem I, Meaney S. Brain cholesterol: Long secret life behind a barrier. Arterioscler Thromb Vasc Biol 2004; in press
23. Wood WG, Igbavboa U. Cholesterol trafficking and amyloid beta peptides. Pharmacopsychiatry 2003; Suppl. 2: S144-S148
24. Eckert GP, Kirsch C, Leutz S, et al. Cholesterol modulates beta-peptide's membrane interactions. Pharmacopsychiatry 2003; Suppl. 2: S136-S144
25. Perry G, Cash AD, Smith MA. Alzheimer disease and oxidative stress. J Biomed Biotechnol 2002; 2: 120-123
26. de la Monte SM, Ganju N, Feroz N, et al. Oxygen free radical injury is sufficient to cause some Alzheimer-type molecular abnormalities in human CNS neuronal cells. J Alzheimer Dis 2000; 2: 261-281
27. Butterfield DA, Griffin S, Munch G, et al. Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. J Alzheimer Dis 2002; 4: 193-201
28. Butterfield DA, Castegna A, Lauderback CM, et al. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging 2002; 23: 655-664
29. Choi J, Malakowsky CA, Talent JM, et al. Anti-apoptotic proteins are oxidized by Aβ25-35 in Alzheimer's fibroblasts. Biochim Biophys Acta 2003; 1637: 135-141
30. Korolainen MA, Goldsteins G, Alafuzoff I, et al. Proteomic analysis of protein oxidation in Alzheimer's disease brain. Electrophoresis 2002; 23: 3428-3433
31. Castegna A, Thongboonkerd V, Klein JB, et al. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 2003; 85: 1394-1401
32. de la Torre JC. Alzheimer disease as a vascular disorder. Stroke 2002; 33: 1152-1162
33. de la Torre JC, Stefano GB. Evidence that Alzheimer's disease is a microvascular disorder: The role of constitutive nitric oxide. Brain Res Rev 2000; 34: 119-136
34. Luth HJ, Munch G, Arendt T. Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. Brain Res 2002; 953: 135-143
35. Colton CA, Brown CM, Cook D, et al. APOE and the regulation of microglial nitric oxide production: A link between genetic risk and oxidative stress. Neurobiol Aging 2002; 23: 777-785
36. de la Monte SM, Chiche J, von dem Bussche A, et al. Nitric oxide synthase-3 overexpression causes apoptosis and impairs neuronal mitochondrial function: Relevance to Alzheimer's-type neurodegeneration. Lab Invest 2003; 83: 287-298
37. Drake J, Link CD, Butterfield DA. Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide(1-42) in a transgenic Caenorhabditis elegans model. Neurobiol Aging 2003; 24: 415-420
38. Butterfield DA. Amyloid beta-peptide(1-42)-induced oxidative stress and neurotoxicity: Implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radical Res 2002; 36: 1307-1313
39. Cacabelos R, Alvarez XA, Lombardi V, et al. Pharmacological treatment of Alzheimer disease: From phychotropic drugs and cholinesterase inhibitors to pharmacogenomics. Drugs Today 2000; 36: 415-499
40. Cacabelos R. The application of functional genomics to Alzheimer's disease. Pharmacogenomics 2003; 4: 597-621
41. Cacabelos R, Beyer K, Lao JI, et al. Association of genetic risk factors in Alzheimer's disease and a novel mutation in the predicted TM2 domain of presenilin-2 in late-onset AD. In: Iqbal K, Swaab DF, Winblad B, et al., eds. Alzheimer's Disease and Related Disorders. Chichester: Wiley, 1999; pp. 93-102
42. Cacabelos R, Fernández-Novoa L, Lombardi V, et al. Genetic variation and pharmacogenomics in Alzheimer disease. Psychiat Neurol Jap 2003; 105: 47-67
43. Cacabelos R. Pharmacogenomics in Alzheimer's disease. Min Rev Med Chem 2002; 2: 59-84
44. Cacabelos R. Pharmacogenomics for the treatment of dementia. Ann Med 2002; 34: 357-379
45. Cacabelos R, Alvarez A, Fernández-Novoa L, et al. A pharmacogenomic approach to Alzheimer's disease. Acta Neurol Scand 2000; Suppl. 176: 12-19
46. Cacabelos R, Lombardi V, Fernández-Novoa L, et al. A functional genomics approach to the analysis of biological markers in Alzheimer disease. In: Takeda M, Tanaka T, Cacabelos R, eds. Molecular Neurobiology of Alzheimer Disease and Related Disorders. Basel, Karger, 2004: 236-285
47. Rapoport SI. Coupled reductions in brain oxidative phosphorylation and synaptic function can be quantified and staged in the course of Alzheimer disease. Neurotox Res 2003; 5: 385-398
48. Kulasingam SL, Samsa GP, Zarin DA, et al. When should functional neuroimaging techniques be used in the diagnosis and management of Alzheimer's dementia? A decision analysis. Value Health 2003; 6: 542-550
49. www.ncbi.nlm.nih.gov/LocusLink
50. Cacabelos R. Diagnosis of Alzheimer's disease: Defining genetic profiles (genotype versus phenotype). Acta Neurol Scand 1996; Suppl. 165: 72-84
51. Zamrini E, Parrish JA, Parsons D, et al. Medical comorbidity in black and white patients with Alzheimer's disease. South Med J 2004; 97: 2-6
52. Li L, Cao D, Garber DW, et al. Association of aortic atherosclerosis with cerebral beta-amyloidosis and learning deficits in a mouse model of Alzheimer's disease. Am J Pathol 2003; 163: 2155-2164
53. Paris D, Humphrey J, Quadros A, et al. Vasoactive effects of Aβ in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: Role of inflammation. Neurol Res 2003; 25: 642-651
54. Tan Zs, Seshadri S, Beiser A, et al. Plasma total colesterol level as a risk factor for Alzheimer disease: The Framingham study. Arch Intern Med 2003; 163: 1053-1057
55. Poirier J. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol Med 2003; 9: 94-101
56. Michikawa M. The role of cholesterol in pathogenesis of Alzheimer's disease: Dual metabolic interaction between amyloid and cholesterol. Mol Neurobiol 2003; 27: 1-12
57. Launer LJ, White LR, Petrovitch H, et al. Cholesterol and neuropathologic markers of AD: A population-based autopsy study. Neurology 2001; 23: 1447-1452
58. Puglielli L, Tanzi RE, Kovacs DM. Alzheimer's disease: The cholesterol connection. Nat Neurosci 2003; 6: 345-351
59. Burns MP, Noble WJ, Olm V, et al. Co-localization of cholesterol, apolipoprotein E and fibrillar Aβ in amyloid plaques. Brain Res Mol Brain Res 2003; 110: 119-125
60. Ehehalt R, Keller P, Haass C, et al. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipids rafts. J Cell Biol 2003; 160: 113-123
61. Eckert GP, Kirsch C, Muller WE. Brain-membrane cholesterol in Alzheimer's disease. J Nutr Health Aging 2003; 7: 18-23
62. Sparks DL, Lopez J, Connor D, et al. A position paper: Based on observational data indicating an increased rate of altered blood chemistry requiring withdrawal from the Alzheimer's Disease Cholesterol-Lowering Treatment Trial (ADCLT). J Mol Neurosci 2003; 20: 407-410
63. Sjogren M, Gustafsson K, Syversen S, et al. Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein. Dement Geriatr Cogn Disord 2003; 16: 25-30
64. Champagne D, Pearson D, Dea D, et al. The cholesterol-lowering drug probucol increases apolipoprotein E production in the hippocampus of aged rats: Implications for Alzheimer's disease. Neuroscience 2003; 121: 99-110
65. Park IH, Hwang EM, Hong HS, et al. Lovastatin enhances Aβ production and senile plaque deposition in female Tg2576 mice. Neurobiol Aging 2003; 24: 637-643
66. Meske V, Albert F, Richter D, et al. Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: Implications for Alzheimer's disease. Eur J Neurosci 2003; 17: 93-102
67. Kolsch H, Ptok U, Mohamed I, et al. Association of the C766T polymorphism of the low-density lipoprotein receptor-related protein gene with Alzheimer's disease. Am J Med Genet 2003; 15: 128-130
68. Papassotiropoulos A, Streffer JR, Tsolaki M, et al. Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch Neurol 2003; 60: 29-35
69. Sun Y, Yao J, Kim TW, et al. Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion. J Biol Chem 2003; 278: 27688-27694
70. Wollmer MA, Streffer JR, Lutjohann D, et al. ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease. Neurobiol Aging 2003; 24: 421-426
71. Teunissen CE, Lutjohann D, von Bergmann K, et al. Combination of serum markers related to several mechanisms in Alzheimer's disease. Neurobiol Aging 2003; 24: 893-902
72. Reiman EM, Chen K, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci USA 2004; 101: 284-289
73. Nestor PJ, Fryer TD, Ikeda M, et al. Retrospenial cortex (BA 29/30) hypometabolism in mild cognitive impairment (prodromal Alzheimer's disease). Eur J Neurosci 2003; 18: 2663-2667
74. Lombardi VR, García M, Rey L, et al. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's disease individuals. J Neuroimmunol 1999; 97: 163-171
75. Cacabelos R, Fernández-Novoa L, et al. Pharmacogenomic studies with a combination therapy in Alzheimer's disease. In: Takeda M, Tanaka T, Cacabelos R, eds. Molecular Neurobiology of Alzheimer Disease and Related Disorders. Basel: Karger, 2004: 94-107
76. Marcotte ER, Srivastava LK, Quirion R. cDNA microarray and proteomic approaches in the study of brain diseases: Focus on schizophrenia and Alzheimer's disease. Pharmacol Ther 2003; 100: 63-74
77. Butterfield DA, Boyd-Kimball D, Castegna A. Proteomics in Alzheimer's disease: Insights into potential mechanisms of neurodegeneration. J Neurochem 2003; 86: 1313-1327
78. Chen W, Ji J, Xu X, et al. Proteomic comparison between human young and old brains by two-dimensional gel electrophoresis and identification of proteins. Int J Dev Neurosci 2003; 21: 209-216
79. de la Torre J. Is Alzheimer's a neurodegenerative or a vascular disorder? Data, dogma and dialectics. Lancet Neurol 2004; 3: 184-190
80. Plomin R, Spinach FM. Intelligence: Genetics, genes, and genomics. J Pers Soc Psychol 2004; 86: 112-129
81. Klein JB, Gozal D, Pierce WM, et al. Proteomic identification of a novel protein regulated in CA1 and CA3 hippocampal regions during intermittent hypoxia. Respir Physiol Neurobiol 2003; 136: 91-103
82. Lu A, Tang Y, Ran R, et al. Genomics of the preriinfarction cortex after focal cerebral ischemia. J Cereb Blood Flow Metab 2003; 23: 786-810